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Abstract
Background: Periodontitis is a common, chronic inflammatory disease caused by gram-negative bacteria
leading to destruction of tissues supporting the teeth. Epidemiological studies have consistently shown
increased frequency, extent and severity of periodontitis among diabetic adults. More recently, some
controlled clinical trials have also suggested that periodontal treatment could improve glycaemic control
in diabetic patients. However current evidence does not provide sufficient information on which to
confidently base any clinical recommendations. The main objective of this clinical trial is to assess whether
periodontal treatment could lead to a decrease in glycated haemoglobin levels in metabolically unbalanced
diabetic patients suffering from chronic periodontitis.
Methods: The DIAPERIO trial is an open-label, 13-week follow-up, randomized, controlled trial. The total
target sample size is planned at 150 participants, with a balanced (1:1) treatment allocation (immediate
treatment vs delayed treatment). Periodontal treatment will include full mouth non-surgical scaling and
root planing, systemic antibiotherapy, local antiseptics (chlorhexidine 0.12%) and oral health instructions.
The primary outcome will be the difference in change of HbA1c between the two groups after the 13-
weeks' follow-up. Secondary outcomes will be the difference in change of fructosamine levels and quality
of life between the two groups.
Discussion: The DIAPERIO trial will provide insight into the question of whether periodontal treatment
could lead to an improvement in glycaemic control in metabolically unbalanced diabetic patients suffering
from periodontitis. The results of this trial will help to provide evidence-based recommendations for
clinicians and a draft framework for designing national health policies.
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Background
Periodontitis is a common, chronic inflammatory disease
caused by gram-negative infection leading to the destruc-
tion of tissues supporting the teeth. Approximately 50%
of adults in the United States have chronic periodontitis
[1] and similar rates have been reported in France [2].
Diabetes is a metabolic disorder characterized by high
blood glucose levels. It is a significant cause of morbidity
and mortality in both developed and developing coun-
tries. Its prevalence for all age-groups worldwide has been
estimated at 2.8% in 2000 and 4.4% in 2030 [3].
The relationship between these two affections has been
largely described in the literature over the past 50 years.
Epidemiological studies have consistently shown
increased frequency, extent and severity of periodontitis
among diabetic adults [4]. More recently, some controlled
clinical trials have also suggested that periodontal treat-
ment could improve glycaemic control in diabetic
patients [5-10]. We previously conducted a systematic
review of the literature and found that results were con-
flicting across trials [11].
This could be attributed to considerable differences in
methodology and also in the sample sizes and composi-
tions of the groups included in the studies. The study by
Jones et al. [6] was the best quality study that we assessed
in the meta-analysis but the subjects enrolled in this trial
were highly specific (American veterans, mainly males,
smokers, with poorly controlled diabetes). Other studies
showed evidence of methodological deficiencies (mainly
small sample sizes). Further, the majority of clinical trials
on this topic have included subjects with poorly control-
led diabetes (HbA1c > 9%) [11]. We argue that periodon-
tal treatment to improve glycaemic control in diabetic
patients would be more relevant among patients with
moderately poor glycaemic control (HbA1c between 7.0
and 9.5%). Interventions other than periodontal treat-
ment (e.g. adequate medical treatment) are likely to be
more effective in reducing HbA1c levels in poorly control-
led diabetic patients.
Our systematic review emphasized the need to conduct a
well-designed randomized controlled trial in a European
population, among patients with suboptimal glycated
haemoglobin levels, according to clinical recommenda-
tions for the treatment of chronic periodontitis in diabetic
subjects.
Methods
The DIAPERIO trial is an open-label, 13-week follow-up,
randomized, controlled trial. The design specifies a bal-
anced (1:1) treatment allocation.
Objectives
The main objective of this study is to assess whether peri-
odontal treatment could lead to a decrease in glycated
haemoglobin (HbA1c) levels in metabolically unbal-
anced diabetic patients suffering from periodontitis. We
will therefore test the null hypothesis that periodontal
treatment does not reduce the HbA1c level in metaboli-
cally unbalanced diabetic patients suffering from perio-
dontitis.
The secondary objectives of this study are to assess, among
metabolically unbalanced diabetic patients suffering from
periodontitis:
￿ whether periodontal treatment could lead to a
decrease in fructosamine levels,
￿ whether periodontal treatment could lead to an
improvement in quality of life.
Study participants
Setting and location
Volunteers will be recruited in the Diabetology Depart-
ments of two University Hospitals of south-western
France (Toulouse-Rangueil Teaching Hospital and Bor-
deaux-Haut-l'Eveque Teaching Hospital). Subjects will be
selected in two steps: a screening visit at the Diabetology
Department, and an inclusion visit at the Dental Care
Department of the same University Hospital. Periodontal
treatments and follow-up visits will be performed in the
Dental Care Departments (Figure 1).
Eligibility criteria
Eligibility criteria will be assessed in the Diabetology and
Dental Care departments at V0 and V1 respectively.
At V0 (Diabetology Department)
During the study period, all consecutive patients who con-
sult in the Diabetology Departments will be screened for
possible inclusion in the trial. Pre-inclusion and non-
inclusion criteria will be checked by diabetologists using a
standardized questionnaire.
Pre-inclusion criteria (V0)
To be pre-included, patients will have to:
- be aged 18 years or older (male or female),
- be affiliated to a public health system,
- be diagnosed as having had type 1 or 2 diabetes for at
least one year before V0,
- have a last known value of HbA1c, measured within
three months prior V0, between 6.8% and 9.7%,Trials 2009, 10:65 http://www.trialsjournal.com/content/10/1/65
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- have received stable antidiabetic therapy (no changes to
diet, medication, dosage or formulation) during the three
months preceding V0,
- have at least six natural permanent teeth,
- be available for all study visits over three months in the
Dental Care Departments (V1 to V6),
- be able to give their written informed consent.
Non-inclusion criteria (V0)
Several non-inclusion criteria will also be checked in the
Diabetology Departments. Patients will not qualify for
enrolment if they:
- have severe difficulties in understanding written and
spoken French,
- are participating in another intervention study,
- do not have a known value of HbA1c level,
- have a known diabetes complication leading to planned
hospitalization within 4 months after the screening visit,
- have a known pathological condition leading to planned
hospitalization within 4 months after the screening visit,
- are suffering from one or more known infectious dis-
eases (HIV, hepatitis, infectious mononucleosis),
- are suffering from known clinically significant renal dis-
ease (creatinine clearance <60 ml/min), or liver disease,
- have known phenylketonuria,
- have a known risk of endocarditis,
- have a permanent pacemaker,
- suffer from a chronic disorder that requires chronic or
intermittent use of corticosteroids and/or antibiotics,
- are taking antithrombotic treatment,
- have known hypersensitivity to chlorhexidine gluconate,
- have known contraindications to both amoxicillin and
clindamycin,
Study timelines Figure 1
Study timelines.
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- for females: are pregnant or intending to become preg-
nant, or lactating.
Subjects satisfying the pre-inclusion criteria and exempt
from the non-inclusion criteria at V0 will be given the pos-
sibility of further participating in the trial and will be
given a scheduled appointment at the Dental Care Depart-
ment (V1) within 3 weeks after V0 (Figure 1).
At V1 (Dental Care Department)
Non-inclusion and inclusion criteria will be checked by
trained dentists-examiners, using a standardized ques-
tionnaire and a calibrated examination method.
Non-inclusion criteria (V1)
At this stage, patients will not qualify for enrolment if they
present at least one of the following: acute oral infection,
acute oral pain (including pulpitis), suspicious oral
mucosal lesion, severe oral inflammation unrelated to
periodontal conditions, or need for immediate tooth
extractions. Patients with any of the above problems will
be offered treatment in the Dental Care Department as
routine patients. Inclusion will be reconsidered after
remission of the condition(s).
Inclusion criteria (V1)
Final inclusion will be decided at the Dental Care Depart-
ments, during the inclusion visit (V1). The criteria for
inclusion are:
- written informed consent,
- no change relative to pre-inclusion criteria and non-
inclusion criteria since V0,
- patient with periodontitis. Periodontitis is defined by the
presence of one site with periodontal probing depth
(PPD) ≥ 4 millimetres and clinical attachment level (CAL)
≥ 3 millimetres on at least 4 teeth.
- patient with HbA1c level ≥ 7.0% and ≤ 9.5%. Blood sam-
ples will be taken during V1, after periodontal assessment.
Thus blood will only be taken from patients with perio-
dontitis.
Subjects fulfilling all the inclusion criteria and none of the
non-inclusion criteria at V1 will be randomized and will
be given a scheduled appointment at the Dental Care
Department, within 10 days for the treatment group (V2),
and between 21 and 31 days from V1 for the control
group (V3) (Figure 1).
Intervention
Periodontal treatment will include non-surgical scaling
and root planing, systemic antibiotherapy, and oral
health instructions.
• Scaling and root planing (SRP)
This will be performed at V2 for the treatment group, and
at V5 for the control group (Figure 1). Non-surgical perio-
dontal therapy will be performed during a 2-hour, single-
session, full-mouth ultrasonic debridement by trained
dentists-examiners, who will receive special training from
a periodontist prior to the beginning of the study.
Disclosing solution will be used to visualize the plaque for
the clinician. Then scaling and root planing will involve
removal of supra- and sub-gingival plaque from all tooth
surfaces, and removal of supra- and sub-gingival calculus
with both ultrasonic and hand instruments (Gracey
curettes). Mechanical debridement will be performed
under local anaesthesia if necessary. Scaling and root
planing will be combined with subgingival irrigation
using an antiseptic mouth rinse (chlorhexidine 0.12%).
Finally, the coronal and radicular surfaces of the teeth will
be polished.
￿ Systemic antibiotherapy (ATB)
The French health authorities recommend the prescrip-
tion of systemic antibiotherapy for metabolically unbal-
anced diabetic patients receiving periodontal treatment
[12,13]. On primary intention, capsules of 500 mg amox-
icillin will be prescribed to patients 3 times a day (morn-
ing, midday and evening) for 7 days. Two boxes of 12
capsules will be given to the patients after scaling and root
planing (at V2 for the treatment group and at V5 for the
control group). In case of contraindication to beta-lactam
antibiotics, capsules of 300 mg clindamycin will be pre-
scribed to patients twice a day (morning and evening) for
7 days. One box of 16 capsules will be given to the
patients after scaling and root planing (at V2 for the treat-
ment group and at V5 for the control group). These anti-
biotics are recommended by French health authorities for
the treatment of chronic periodontitis in diabetic patients
[13].
￿ Oral health instructions (OHI)
After periodontal treatment, subjects will receive oral
health instructions from the dentist that performed the
scaling and root planing. These instructions will be given
at V2 and V3 for the treatment group and at V5 and V6 for
the control group. A 15-minute oral session will include
verbal and visual information on how to use toothbrush,
floss and interspace brushes, how to clean bridges and
dentures, how and why to use a plaque disclosing test and
a mouthwash.
A pack containing all the dental care products necessary
for 3-months of periodontal maintenance will be given to
the subjects at V2 for the treatment group and V5 for the
control group. It will include three 75 ml tubes of tooth-
paste, three soft toothbrushes, 12 single-tufted interspace
brushes, and sufficient dental floss and plaque disclosingTrials 2009, 10:65 http://www.trialsjournal.com/content/10/1/65
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tablets for a daily use over 3 months. An antiseptic mouth-
wash (chlorhexidine 0.12%) will also be given for mouth
washing three times a day for 10 days after the scaling and
root planing session.
Finally, the pack will contain leaflets that will provide pic-
torial information relative to the method, the frequency
and the duration of each procedure.
Subjects in the control group will receive neither perio-
dontal treatment nor a placebo during the 3-months fol-
low-up (from V1 to V4). They will receive the same
periodontal treatment as subjects in the treatment group
(non-surgical scaling and root planing, systemic antibio-
therapy, two-sessions of oral health instructions and anti-
septic prescription) at V5 and V6 (Figure 1).
Outcomes
HbA1c
The primary outcome of the DIAPERIO trial will be the
difference in change of HbA1c from V1 to V4 between the
two groups. The HbA1c level is proportional to average
blood glucose concentration over the previous 1 to 3
months.
Fructosamine
A secondary outcome will be the difference in change of
fructosamine levels from V1 to V3 and from V1 to V4
between the two groups. Fructosamine reflects an average
of blood glucose levels over a period of 2 to 3 weeks.
Quality of life
A pragmatic outcome will be the difference in change in
the quality of life between the two groups from V1 to V4.




A full-mouth periodontal examination will be performed
by trained dentists-examiners at V1 and V4 for both
groups. The clinical examination will include depth of
periodontal pockets (PPD in mm), level of clinical attach-
ment (CAL in mm) and bleeding on probing (BOP: yes/
no). Values will be taken for all scorable teeth at six sites
per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-
lingual, mid-lingual and disto-lingual). No radiographs
will be taken. The result of the periodontal treatment will
be assessed on the healing response in the tissues using
PPD, CAL, BOP, and the amount of inflamed periodontal
tissue (PISA)[14].
Questionnaires
At V1 and at V4, subjects will complete a questionnaire
designed to gauge medical, social and oral health behav-
ioral information. The questionnaire completed at V4 will
assess the evolution of oral health behavior during the 3-
months follow-up. Adverse events will also be reported.
Reportable adverse events will include unexpected study-
related events (oral adverse events) and serious adverse
events regardless of cause.
Randomization
Randomization will be blocked by centre. Subjects meet-
ing eligibility criteria at V1 will be randomly assigned to
receive periodontal treatment within 10 days (treatment
group) or delayed periodontal treatment (control group)
with the use of a block stratified according to clinical cen-
tre.
Study timelines
The DIAPERIO trial will include 4 phases: pre-inclusion,
inclusion-randomization, follow-up and post-follow-up
(Figure 1). Maximum study length per participant will be
30 weeks. No longer term follow-up is planned. Table 1
shows the study schedule. V2 only concerns subjects from
the treatment group, while V5 and V6 only concern sub-
jects from the control group (delayed treatment).
Statistical methods
Sample size calculation was based on detecting a differ-
ence of 0.5% in HbA1c change from baseline between the
two groups. Assuming a standard deviation of 1.0% and
using a 2-sided test at 5% significance level, 64 partici-
pants per group would yield 80% power. Anticipating a
15% dropout rate, the target sample size was thus planned
at 150 participants.
Baseline characteristics by group will be presented as
mean (SD) for continuous variables and tallied for cate-
gorical variables. The intention-to-treat population will
consist of all randomized subjects whereas the evaluable
population will consist of subjects from the intention-to-
treat population who complete the 3-months follow-up.
Descriptive statistics will be provided for the intention-to-
treat population.
All primary analyses will be performed according to inten-
tion-to-treat principles, on the evaluable population (i.e.
all patients with initial (V1) and final (V4) HbA1c meas-
urements), regardless of the subject's presence at interme-
diate visits or his/her degree of compliance with the
treatment. Subjects with missing initial or final HbA1c
measurements will be excluded from the analysis. The
main analysis will be a comparison between the two study
groups concerning the change in the HbA1c levels from
baseline to 3 months in an analysis of covariance
(ANCOVA) model, adjusted for the baseline HbA1c level
and clinical centre. Residual values will be examined for
an approximate normal distribution. If HbA1c values areTrials 2009, 10:65 http://www.trialsjournal.com/content/10/1/65
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highly skewed, a transformation or non-parametric
method will be used instead [15].
The data will also be analysed using the "per protocol"
approach. Here the analysis will be restricted to partici-
pants who were compliant with the treatment protocol
(SRP, ATB and OHI).
In addition to the primary analysis, five binary outcomes
for HbA1c at 3 months (a relative decrease of ≥10%, a
three-month level of < 7%, an absolute decrease of ≥0.5%,
a relative increase of ≥10% and an absolute increase of
≥0.5%) will be evaluated in logistic regression models
adjusted for the baseline HbA1c level and clinical centre
[16].
For secondary outcomes, all continuous variables will be
analysed via analysis of covariance using a model similar
to that specified for the primary outcome. Analyses of
binary variables will be based on logistic regression mod-
els adjusted for group and clinical centre. For secondary
analyses, missing values will be imputed using the Last
Observation Carried Forward method. The safety and effi-
cacy of periodontal treatment will be assessed [17], as will
the correlation between clinical response to periodontal
treatment and HbA1c levels [18]. The proportion of sub-
jects who had one or more adverse events in the two
groups will be compared by means of Fisher's exact test.
Ethical aspects
All participants will have to provide written informed
consent. The informed consent form will contain the fol-
lowing information: names and affiliations of investiga-
tors, a plain language description of the study (treatment
group, control group and intervention), the duration of
the study, the right to withdraw at any time, the ethics
committee approval and the privacy guarantee. All partic-
ipants will receive free periodontal treatment (immediate
or delayed).
The protocol and procedures have been approved by eth-
ics and regulatory agencies and are implemented in
accordance with provisions of the Declaration of Helsinki
and French Good Clinical Practice guidelines for perio-
dontal treatment in diabetic patients. The appropriate
Committee for Protection of Research Subjects (Comité
de Protection des Personnes [CPP], Sud-Ouest Outre-Mer
I), approved the protocol on February 23rd, 2009. The
Sanitary Safety of Health Products Agency (Agence
française de sécurité sanitaire des produits de santé [AFSS-
APS]), approved it on February 12th, 2009 (ref: 2008-
A01467-48). The Advisory Committee for Data Process-
ing in Health Research (Comité consultatif sur le traite-
ment de l'information en matière de recherche dans le
domaine de la santé [CCTIRS]), gave its approval on Jan-
uary 15th, 2009.
Discussion
We aim to use a two-centre, randomized, controlled trial
to investigate whether periodontal treatment could lead
Table 1: Study schedule.
V0 V1 V2 V3 V4 V5 V6
Treatment group
Review of pre-inclusion criteria *
Review of inclusion criteria *
Written informed consent *
Full periodontal assessment * *
Initial questionnaire + SF-36 *
Blood collection (HbA1c) * *
Blood collection (fructosamine) * * *
Periodontal treatment (SRP) *
Oral hygiene instructions * *
Final questionnaire + SF-36 *
Appointment for a next visit * * * *
Control group
Review of pre-inclusion criteria *
Review of inclusion criteria *
Written informed consent *
Full periodontal assessment * *
Initial questionnaire + SF-36 *
Blood collection (HbA1c) * *
Blood collection (fructosamine) * * *
Periodontal treatment (SRP) *
Oral hygiene instructions * *
Final questionnaire + SF-36 *
Appointment for a next visit * * * * *Publish with BioMed Central    and   every 
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to an improvement in glycaemic control in metabolically
unbalanced diabetic patients suffering from periodontitis.
The results of this trial will help to provide evidence-based
recommendations for clinicians and a draft framework for
designing local and national health policies.
Abbreviations
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SRP: scaling and root planing.
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